ArticleHaematologica2019

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Arnon P Kater et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.